.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Queensland Health
Novartis
Merck
Boehringer Ingelheim
Harvard Business School
Farmers Insurance
Chubb
Fish and Richardson
Johnson and Johnson

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,940,330

« Back to Dashboard

Which drugs does patent 8,940,330 protect, and when does it expire?


Patent 8,940,330 protects ZUBSOLV and is included in one NDA. There have been four Paragraph IV challenges on Zubsolv.

This patent has twenty-eight patent family members in twenty-five countries.

Summary for Patent: 8,940,330

Title:Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
Inventor(s): Fischer; Andreas (Uppsala, SE)
Assignee: Orexo AB (Uppsala, SE)
Application Number:14/127,470
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Orexo Us IncZUBSOLVbuprenorphine hydrochloride; naloxone hydrochlorideTABLET;SUBLINGUAL204242-006Oct 4, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Orexo Us IncZUBSOLVbuprenorphine hydrochloride; naloxone hydrochlorideTABLET;SUBLINGUAL204242-001Jul 3, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Orexo Us IncZUBSOLVbuprenorphine hydrochloride; naloxone hydrochlorideTABLET;SUBLINGUAL204242-005Jun 4, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Orexo Us IncZUBSOLVbuprenorphine hydrochloride; naloxone hydrochlorideTABLET;SUBLINGUAL204242-002Jul 3, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Orexo Us IncZUBSOLVbuprenorphine hydrochloride; naloxone hydrochlorideTABLET;SUBLINGUAL204242-003Dec 11, 2014RXYesNo► Subscribe► SubscribeY► Subscribe
Orexo Us IncZUBSOLVbuprenorphine hydrochloride; naloxone hydrochlorideTABLET;SUBLINGUAL204242-004Dec 11, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,940,330

PCT Information
PCT FiledSeptember 18, 2012PCT Application Number:PCT/GB2012/052303
PCT Publication Date:March 28, 2013PCT Publication Number: WO2013/041851

Non-Orange Book Patents for Patent: 8,940,330

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,259,421Abuse-resistant pharmaceutical composition for the treatment of opioid dependence► Subscribe
9,439,900Abuse-resistant pharmaceutical composition for the treatment of opioid dependence► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,940,330

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore2014009401► Subscribe
Serbia53995► Subscribe
Portugal2706986► Subscribe
Peru11982014► Subscribe
New Zealand709502► Subscribe
New Zealand618120► Subscribe
Mexico2014002556► Subscribe
South Korea20140075682► Subscribe
Japan2017171687► Subscribe
Japan6210988► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Chubb
Farmers Insurance
Julphar
Healthtrust
Daiichi Sankyo
Cerilliant
Baxter
Citi
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot